Lundbeck’s plans to expand its use hit a snag after the drug failed a phase 3 trial designed to accelerate its approval in China and other Asian markets, while competition in the migraine ...

Lundbeck has received additional label expansions for Trintellix and has seen strong uptake in Europe, Japan, and China. The patents covering Trintellix expire between 2022 and 2031, but the ...

Lundbeck A/S (Lundbeck ... The system is being broadly adopted worldwide, including regulatory nods in China and Australia and a launch in Japan after obtaining reimbursement approval.

No-moat Lundbeck delivered strong year-end results with revenue growing nearly 11% year over year to DKK 22 billion. Strong demand of Lundbeck’s strategic brands (Vyepti, Rexulti, Abilify ...